In another case report by Fujino et al., a 31-year-old female patient on semaglutide for T2DM underwent EGD in preparation for bariatric surgery
Patients on tirzepatide lost an average of 20.2% of their body weight over 72 weeks Patients on semaglutide lost an average of 13.7% of their body weight over the same period 47% more tirzepatide patients achieved 25% or greater body weight loss compared to semaglutide Tirzepatide also produced greater reductions in waist circumference across all dose comparisons A 2024 meta-analysis published in JAMA Internal Medicine analyzing real-world data from over 140,000 patients confirmed the same pattern: tirzepatide produced an average of 4.23 kg more weight loss than semaglutide across all doses and durations studied

Elevated potassium levels, known as hyperkalemia, must be monitored carefully because, if left unchecked, they can lead to serious complications, including abnormal heart rhythms and, in severe cases, death. Accordingly, it is generally not prescribed to people with certain underlying health conditions, including kidney disease, where the risk of elevated potassium levels is higher, or those with very low blood pressure
Resistance Training: Essential, Not Optional Strength training signals your body to preserve muscle despite caloric deficit